The few European stock exchanges that opened today, on Christmas Eve, ended the trading session on Friday with small losses, with the trading volume remaining limited.
On the board, the STOXX 600 is down 0.1%, with the index recording weekly gains of 1.9%. The pan-European index enters the holiday season having made an impressive rally of 21% since the beginning of the year, after the fall of 2020 by 4%.
The STOXX 600 rally followed the very easing direction of monetary policy in Europe and the US and strong corporate results, despite the turmoil in global supply chains and the jump in inflation this year.
The British FTSE 100 closed with marginal losses of 0.02% at 7,372.10 points, ending an upward series of three consecutive sessions. The French CAC 40 fell 0.3% to 7,086.58 points. Markets in Germany, Italy, Spain and Switzerland did not open today, while US markets will remain closed.
Concerns over the micron prevailed earlier this week as the rapid spread of the new mutation has forced European governments to return to strict measures to curb social activity in an effort to curb the spread of the virus.
Encouraging data in recent studies on micron, however, have given a valuable boost to investment psychology, allaying concerns about the risk that the new executive will derail the global recovery.
According to a study from South Africa published this week, the disease caused by the Omicron variant of the coronavirus is 70% to 80% less severe than Delta.
At the same time, a separate study in Scotland showed that Omicron was associated with a two-thirds reduction in the risk of hospitalization for Covid-19 compared to Delta. The British Agency for Health Protection supported these findings, stating that a patient with a micron is 50-70% less likely to be hospitalized compared to the delta strain. However, the very high transmission of omicron can lead to large numbers of hospitalizations.
The decision of the American authorities to give the “green light” for emergency use of Merck antiviral pill against Covid, just one day after the approval of the corresponding drug of Pfizer, also gave impetus to the investment psychology.
.
I am Sophia william, author of World Stock Market. I have a degree in journalism from the University of Missouri and I have worked as a reporter for several news websites. I have a passion for writing and informing people about the latest news and events happening in the world. I strive to be accurate and unbiased in my reporting, and I hope to provide readers with valuable information that they can use to make informed decisions.
